Evaluation of the Benefit of Ropeginterferon Treatment in Patients with Polycythemia Vera

Results: Twenty-three patients (15 men and 8 women) with a median age of 57 years were enrolled, with 87.5% having the JAK617F mutation. Six patients had a history of thrombosis. Besremi was used as a first-line treatment in 11 patients and as a second-line treatment in 12 patients after Hydroxyurea...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:Documenta Haematologica
المؤلفون الرئيسيون: Diana GRASU, Viola Maria POPOV, Mirela VOICU, Mihaela POPESCU, Oana PATRINOIU, Felicia MIHAI, Geanina OFITERU, Meilin OMER, Mihaela ANDREESCU
التنسيق: مقال
اللغة:الإنجليزية
منشور في: Romanian Society of Hematology 2025-03-01
الموضوعات:
policitemia vera
myeloproliferative neoplasm
ropeginterferon
الوصول للمادة أونلاين:https://www.dhrrh.ro/wp-content/uploads/2025/03/DHRRH-2025-1-art5.pdf

الانترنت

https://www.dhrrh.ro/wp-content/uploads/2025/03/DHRRH-2025-1-art5.pdf

مواد مشابهة